A new form of proton therapy designed to deliver cancer-killing radiation therapy in less than a second, through fewer total sessions, with potentially less risk of damaging side effects, is now being tested in a phase I clinical trial at the Abramson Cancer Center of the University of Pennsylvania.
The REZILIENT3 trial, a global phase III clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations, met its primary endpoint of progression-free survival at a planned interim analysis.
